Sebastien Hazard
Chief Tech/Sci/R&D Officer en IMUNON, INC. .
Fortuna: 32 800 $ al 31/03/2024
Perfil
Sebastien Hazard is currently the Chief Medical Officer & Executive Vice President at Imunon, Inc. Prior to his current position, he held the role of Senior Medical Director-Clinical Development at Tesaro, Inc. from 2016 to 2019.
From 2019 to 2021, he served as the Head-Clinical Development at GSK Plc.
Dr. Hazard then joined Bicycle Therapeutics Plc in 2021 as the Senior VP & Head-Clinical Development, a position he held until 2023.
Hazard obtained an MBA from INSEAD.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
IMUNON, INC.
0.21% | 07/12/2023 | 20 000 ( 0.21% ) | 32 800 $ | 31/03/2024 |
Cargos activos de Sebastien Hazard
Empresas | Cargo | Inicio |
---|---|---|
IMUNON, INC. | Chief Tech/Sci/R&D Officer | 11/12/2023 |
Antiguos cargos conocidos de Sebastien Hazard.
Empresas | Cargo | Fin |
---|---|---|
BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 01/09/2023 |
GSK PLC | Chief Tech/Sci/R&D Officer | 01/04/2021 |
TESARO INC | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Formación de Sebastien Hazard.
INSEAD | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
IMUNON, INC. | Health Technology |
GSK PLC | Health Technology |
BICYCLE THERAPEUTICS PLC | Health Technology |
Empresas privadas | 1 |
---|---|
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Sebastien Hazard